Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
46 hedge funds and large institutions have $45.4M invested in Osiris Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
53% more capital invested
Capital invested by funds: $29.6M → $45.4M (+$15.8M)
44% more funds holding
Funds holding: 32 → 46 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cloverdale Capital Management
Dallas,
Texas
|
+$6.68M |
| 2 |
GF
Gabelli Funds
Rye,
New York
|
+$1.49M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$988K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$983K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$767K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$5.71M |
| 2 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$303K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$275K |
| 4 |
WSTAM
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
|
-$61K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$22.5K |
OSIR Hedge Fund Activity: Q4 2018 in Review
46 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q4 2018, worth a combined $45.4M — up 53% from $29.6M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new OSIR positions and 3 closed out — a net gain of 15 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Cloverdale Capital Management, opening a new position worth an estimated $6.68M. The largest seller was Manulife (Manufacturers Life Insurance), cutting an estimated $5.71M.
- 46 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q4 2018, up from 32 in Q3 2018.
- Funds reported $45.4M of Osiris Therapeutics, Inc. Common Stock stock for Q4 2018, up 53% quarter-over-quarter.
- 18 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q4 2018 and 3 closed out, a net change of +15 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q4 2018 was Cloverdale Capital Management, an estimated $6.68M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q4 2018 was Manulife (Manufacturers Life Insurance), an estimated $5.71M sold.
Based on aggregated 13F filings for Q4 2018.